Table 3.
Main adverse events and their severity in 132 patients with advanced PanNET treated with TEM or TEM-CAP
| TEM (n = 38) |
TEM-CAP (n = 94) |
p value | |||
|---|---|---|---|---|---|
| grade 1–2 | grade 3–4 | grade 1–2 | grade 3–4 | ||
| Nausea/vomiting | 15 (39.5) | 1 (2.6) | 42 (44.7) | 2 (2.1) | 0.86 |
| Diarrhea | 4 (10.5) | 0 | 9 (9.6) | 2 (2.1) | 0.66 |
| Neutropenia | 2 (5.3) | 2 (5.3) | 13 (13.8) | 6 (6.4) | 0.35 |
| Thrombocytopenia | 6 (15.8) | 5 (13.2) | 12 (12.8) | 12 (12.8) | 0.89 |
| Anemia | 6 (15.8) | 0 | 16 (17) | 1 (1.1) | 0.80 |
| Stomatitis | 2 (5.3) | 0 | 3 (3.2) | 0 | 0.63 |
| Asthenia | 18 (47.4) | 3 (7.9) | 41 (43.6) | 0 | 0.017 |
| Hand-foot syndrome | 0 | 0 | 13 (13.8) | 3 (2.3) | 0.025 |
Bold type denotes significance. PanNET, pancreatic neuroendocrine tumor; TEM, temozolomide; CAP, capecitabine.